Of note, SLx-2119, that has 100-fold more selectivity towards ROCK2 than ROCK1, has been suggested to be a potential drug for the treatment of ischemic stroke [43], autoimmune disease [44,45] and psoriasis [46]. This evidence concerns the gene ROCK1 and psoriasis.